Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction
NCT06215586Phase 2Completed
- Sponsor
- Cardurion Pharmaceuticals
- Start
- Feb 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 2 trial of tovinontrine in heart failure with preserved ejection fraction (HFpEF), sponsored by Cardurion Pharmaceuticals. Started Feb 2024; status: completed.
02
Drugs
tovinontrine
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT06215586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06215586.